New findings indicate that targeting Polo-like kinase 1 (PLK1) potentiates gemcitabine-induced apoptosis in pancreatic cancer cells, providing a synergistic therapeutic strategy. This study suggests that PLK1 inhibition could improve clinical outcomes for one of the deadliest cancers through enhanced programmed cell death.